All News

Biologic-naïve status and higher inflammation predict rapid skin clearance with psoriasis biologics, while palmoplantar disease may limit response.

Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.

New strategies and therapies are being developed to try and decrease the risk of bone disease and cardiovascular complications among people with severe kidney disease.

A cost model shows anti-VEGF savings only when high injection burden offsets device fees and reading time in AI home OCT vs clinic OCT.

Vutrisiran not only slowed progression to advanced heart failure in patients with ATTR-CM but also reduced mortality and MACE among those who developed advanced disease.

Why Medicaid-covered kids struggle to see pediatricians: low reimbursement and practice deserts in low-income ZIP codes create real barriers to care.

Family caregivers absorb enormous burden after a breast cancer diagnosis, so routine caregiver support is vital.

Health care professionals will gather in Nashville next week for AMCP 2026 to discuss key topics in the space, including AI use and medication access.

Tirzepatide was associated with a significant reduction in a composite of major cardiovascular and kidney outcomes vs the GLP-1 agonist dulaglutide.

Two AAD 2026 posters highlight persistent melanoma disparities: men have worse survival, whereas minority patients are less likely to receive home or hospice end-of-life care.

At-home phototherapy is more convenient than in-office care, and investigators found its one-time costs are also far less than the cost of care in a clinic.

Study finds rural Appalachia faces soaring insomnia and sleep apnea, tied to poverty and stress, urging targeted, equity-focused sleep interventions.

Steven Daveluy, MD, discusses 3-year findings that show 86% of patients remained HS flare-free throughout treatment, reinforcing the case for early intervention.

A real-world study has found that personalizing ibrutinib doses based on patient health does not compromise survival outcomes in chronic lymphocytic leukemia (CLL).

Major health plans cut millions of preapproval hurdles, add 90-day continuity protections, and push real-time e-authorization to speed care access.

A 2026 survey finds 2 in 3 employed adults would be more likely to use GLP-1 weight-loss drugs if employer coverage or behavioral support programs were available.

Both Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores improved after treatment.

Experts outline 4 roles within the value-based care ecosystem that will make it more cohesive and effective for patients.

Ultrasound AI models use radiomics and deep learning to predict DLBCL survival, enabling low-cost, noninvasive risk stratification.

Despite a 24% drop since 2015, over 4 million Americans remain on long-term opioids, and they’re older, on Medicare, and increasingly coprescribed risky drugs.

Medically tailored meals and produce show feasibility but no reduction in 90-day readmissions, according to one study.

Phase 3 CANOPY data show pemivibart safely prevented COVID-19 in patients with CLL, supporting EUA use for immunocompromised populations.

Posttransplant gilteritinib maintenance therapy may boost survival and reduce relapse in relapsed FLT3-mutated acute myeloid leukemia (AML), but larger trials are still needed.

Repeated at-home stool DNA screening shows higher real-world adherence than colonoscopy, boosting early colorectal cancer detection and cutting deaths over 10 years.

Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and formulary incentives.

Poor outcomes could be predicted based on the presence of ectopic germinal centers in the thymus in patients with thymoma-associated myasthenia gravis.

Social determinants of health can delay access to NGS, limiting targeted therapy use and survival outcomes in advanced cancers.

Sequential therapy of ranibizumab and a dexamethasone implant improved results in macular edema secondary to non–ischemic retinal vein occlusion.